On the up and upfront.

Surgical outcomes for intrahepatic cholangiocarcinoma aren’t great. Can neoadjuvant chemo help? There’s no clear guidelines on when to use it, but here’s a sweeping look at its use from 2006-2016 as recorded in the NCDB. While rates of this approach have hovered at 11-16% of cases, its use has appreciably increased prior to node-positive cases. After propensity matching—what else?—the use of neoadjuvant chemo was associated with a 23% relative decrease in mortality. | Mason, Ann Surg Oncol 2021